XML 221 R83.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation (Details)
€ in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 03, 2019
EUR (€)
item
Jul. 24, 2019
EUR (€)
shares
Jul. 23, 2019
Jan. 26, 2018
USD ($)
Jan. 12, 2018
EUR (€)
Jul. 24, 2017
EUR (€)
Jul. 31, 2019
EUR (€)
Apr. 30, 2019
Mar. 31, 2019
shares
Sep. 30, 2018
EUR (€)
Oct. 31, 2017
EUR (€)
Dec. 31, 2017
Dec. 31, 2019
EUR (€)
shares
Dec. 31, 2018
EUR (€)
Dec. 31, 2017
EUR (€)
Apr. 16, 2019
EUR (€)
item
Dec. 28, 2018
USD ($)
Aug. 01, 2018
USD ($)
Mar. 19, 2018
EUR (€)
Oct. 11, 2017
EUR (€)
Jan. 31, 2017
USD ($)
May 11, 2016
USD ($)
Center
item
May 11, 2016
EUR (€)
Center
item
Basis of presentation                                              
Share of Profit (Loss) of Associates and Joint Ventures Accounted for Using Equity Method, Excluding Impairment Loss                         € 8,972                    
Consideration Received in Shares | shares                 1,766,000,000                            
Increase in other current financial asset                         1,717,000                    
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity                         1,716,147 € 465,548 € (389)                
Increase (decrease) through changes in ownership interest on non-controlling interests                         1,511,000                    
Gains from change in contractual right value                         1,000                    
Other current assets                         58,111 42,344                  
Non-controlling interests                                              
Basis of presentation                                              
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity                         1,517,180 € 469,010 € (43)                
Reserves                                              
Basis of presentation                                              
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity                         227,000                    
Translation differences                                              
Basis of presentation                                              
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity                         € (22,009)                    
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.                                              
Basis of presentation                                              
Minority shareholders interest                         45.00%                    
Shanghai RAAS Blood Products, Co. Ltd.                                              
Basis of presentation                                              
Proportion of ownership interest in associate                 26.20%                            
Other current assets                         € 12,000                    
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.                                              
Basis of presentation                                              
Number of shares to be delivered | shares                 90                            
Economic rights (as a percent)                 45.00%                            
Ownership interest acquired (as a percent)                 40.00%                            
Biotest Us Corporation and Haema AG                                              
Basis of presentation                                              
Consideration for sale of subsidiary | $                                 $ 538,014            
Biotest US Corporation                                              
Basis of presentation                                              
Ownership interest acquired (as a percent)                                   100.00%          
Consideration transferred | $                                   $ 286,454          
Haema, AG                                              
Basis of presentation                                              
Ownership interest acquired (as a percent)                                     100.00%        
Consideration transferred                                     € 220,191        
Goetech, LLC. ("MedKeeper")                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)       54.76%                                      
Share capital increase | $       $ 98,000                                      
Aigues Minerals de Vilajuiga, S.A                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)         100.00%                                    
Ownership interest acquired (as a percent)         50.00%                                    
Consideration transferred         € 550                                    
Grifols Malaysia Sdn Bhd                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)                         30.00%                    
Grifols (Thailand) Ltd                                              
Basis of presentation                                              
Number of classes of shares | shares                         2                    
Interstate Blood Bank, Inc., Bio-Blood Components, Inc. and Plasma Biological Services, LLC                                              
Basis of presentation                                              
Cash paid                                           $ 100,000 € 88,215
Call option price | $                                           100,000  
Agreed payment amount for call option                                           $ 10,000 € 9,007
Interstate Blood Bank, Inc                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)               100.00%                              
Ownership interest acquired (as a percent)                                           49.19% 49.19%
Bio Blood Components Inc.                                              
Basis of presentation                                              
Ownership interest acquired (as a percent)                                           48.97% 48.97%
Plasma Biological Services, LLC.                                              
Basis of presentation                                              
Ownership interest acquired (as a percent)                                           48.90% 48.90%
Number of plasma collection centers | Center                                           26 26
Number of blood donation centers | Center                                           9 9
Number of laboratories | item                                           1 1
Kiro Grifols S.L (formerly Kiro Robotics S.L)                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)           90.00%                                  
Ownership interest acquired (as a percent)           40.00%                                  
Consideration transferred           € 12,800                                  
Araclon Biotech , S.L                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent) 75.10%                                            
Number of share capital increases | item 2                             2              
First share capital increase                               € 16,800              
Second share capital increase € 5,900                                            
Progenika Biopharma, S.A.                                              
Basis of presentation                                              
Ownership in subsidiary (as a percent)   100.00% 99.99%                 90.23%                      
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity                     € (374,000)                        
Share capital increase             € 4     € 4,333                          
Cash paid   € 4                                          
Number of shares acquired | shares   33                                          
Progenika Biopharma, S.A. | Grifols Diagnostics Solutions, Inc.                                              
Basis of presentation                                              
Ownership interest acquired (as a percent)                                       0.98%      
Cash paid                                       € 644      
Hologic acquisition                                              
Basis of presentation                                              
Cash paid | $                                         $ 1,865,000    
Grifols Diagnostics Solutions, Inc.                                              
Basis of presentation                                              
Economic rights (as a percent)                 55.00%                            
Voting rights (as percent)                 60.00%                            
Consideration Received in Shares | shares                         1,766,000,000